Clinical trial
RELIEF: Randomized Episodic Versus Long-Term Suppression Experience With…
NCT00219310 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00219310 |
|---|---|
| Title | RELIEF: Randomized Episodic Versus Long-Term Suppression Experience With Famciclovir |
| Official title | A Study to Determine the Safety and Efficacy of Famciclovir in the Episodic and Suppressive Treatment of Recurrent Genital Herpes (RGH). The Study Will Also Evaluate Quality of Life and Patient Satisfaction |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Recurrent Genital Herpes (RGH) |
| Intervention type | Drug |
| Interventions | Famciclovir |
| Start date | Jun 1, 2003 |
| Primary completion | Jun 1, 2005 |
| Completion | Jun 1, 2005 |
| First posted | Sep 22, 2005 |
| Last update posted | Apr 27, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: